# ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT02325557** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advaxis, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Cancer
- Prostate Cancer

## Interventions

- **DRUG:** ADXS31-142
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02325557
- **Lead sponsor:** Advaxis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-04
- **Primary completion:** 2019-08-30
- **Final completion:** 2020-01-22
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325557, "ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02325557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*